An look back at the FDA's relationship with the White House finds that the pair are often at odds and that political concerns have trumped science in recent years as the Obama administration sought to mitigate controversy as it built its case for health care reform.

MASSDEVICE ON CALL — The Obama administration caved in to political pressure on certain measures in attempts to quell controversy as the White House built its case for health care reform, according to a story in the New York Times.
Worried that any political missteps might muddle arguments for reform, the administration delayed important regulations in order to avoid creating an easy target for Republicans.
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
The New York Times lists the 10 most expensive hospitals in the United States, based on CMS data